CRDL
Price
$1.03
Change
+$0.04 (+4.04%)
Updated
Aug 11 closing price
Capitalization
84.1M
6 days until earnings call
EOLS
Price
$5.77
Change
-$0.13 (-2.20%)
Updated
Aug 11 closing price
Capitalization
373.56M
91 days until earnings call
Interact to see
Advertisement

CRDL vs EOLS

Header iconCRDL vs EOLS Comparison
Open Charts CRDL vs EOLSBanner chart's image
Cardiol Therapeutics
Price$1.03
Change+$0.04 (+4.04%)
Volume$1.8M
Capitalization84.1M
Evolus
Price$5.77
Change-$0.13 (-2.20%)
Volume$2.18M
Capitalization373.56M
CRDL vs EOLS Comparison Chart in %
Loading...
CRDL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRDL vs. EOLS commentary
Aug 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRDL is a Hold and EOLS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 12, 2025
Stock price -- (CRDL: $1.03 vs. EOLS: $5.77)
Brand notoriety: CRDL and EOLS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CRDL: 355% vs. EOLS: 153%
Market capitalization -- CRDL: $84.1M vs. EOLS: $373.56M
CRDL [@Pharmaceuticals: Generic] is valued at $84.1M. EOLS’s [@Pharmaceuticals: Generic] market capitalization is $373.56M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $66.04B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRDL’s FA Score shows that 0 FA rating(s) are green whileEOLS’s FA Score has 0 green FA rating(s).

  • CRDL’s FA Score: 0 green, 5 red.
  • EOLS’s FA Score: 0 green, 5 red.
According to our system of comparison, CRDL is a better buy in the long-term than EOLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRDL’s TA Score shows that 6 TA indicator(s) are bullish while EOLS’s TA Score has 4 bullish TA indicator(s).

  • CRDL’s TA Score: 6 bullish, 4 bearish.
  • EOLS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CRDL is a better buy in the short-term than EOLS.

Price Growth

CRDL (@Pharmaceuticals: Generic) experienced а -19.53% price change this week, while EOLS (@Pharmaceuticals: Generic) price change was -36.66% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +5.54%. For the same industry, the average monthly price growth was +11.32%, and the average quarterly price growth was +80.95%.

Reported Earning Dates

CRDL is expected to report earnings on Aug 18, 2025.

EOLS is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+5.54% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EOLS($374M) has a higher market cap than CRDL($84.1M). CRDL YTD gains are higher at: -19.531 vs. EOLS (-47.736). EOLS has higher annual earnings (EBITDA): -30.78M vs. CRDL (-39.96M). EOLS has more cash in the bank: 67.9M vs. CRDL (23.3M). CRDL has less debt than EOLS: CRDL (151K) vs EOLS (130M). EOLS has higher revenues than CRDL: EOLS (275M) vs CRDL (0).
CRDLEOLSCRDL / EOLS
Capitalization84.1M374M22%
EBITDA-39.96M-30.78M130%
Gain YTD-19.531-47.73641%
P/E RatioN/AN/A-
Revenue0275M-
Total Cash23.3M67.9M34%
Total Debt151K130M0%
FUNDAMENTALS RATINGS
CRDL vs EOLS: Fundamental Ratings
CRDL
EOLS
OUTLOOK RATING
1..100
6650
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
92
Overvalued
PROFIT vs RISK RATING
1..100
10080
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9196
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRDL's Valuation (61) in the null industry is in the same range as EOLS (92) in the Pharmaceuticals Major industry. This means that CRDL’s stock grew similarly to EOLS’s over the last 12 months.

EOLS's Profit vs Risk Rating (80) in the Pharmaceuticals Major industry is in the same range as CRDL (100) in the null industry. This means that EOLS’s stock grew similarly to CRDL’s over the last 12 months.

EOLS's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as CRDL (100) in the null industry. This means that EOLS’s stock grew similarly to CRDL’s over the last 12 months.

CRDL's Price Growth Rating (91) in the null industry is in the same range as EOLS (96) in the Pharmaceuticals Major industry. This means that CRDL’s stock grew similarly to EOLS’s over the last 12 months.

CRDL's P/E Growth Rating (100) in the null industry is in the same range as EOLS (100) in the Pharmaceuticals Major industry. This means that CRDL’s stock grew similarly to EOLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRDLEOLS
RSI
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
74%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 13 days ago
85%
Bullish Trend 20 days ago
79%
Declines
ODDS (%)
N/A
Bearish Trend 1 day ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bullish Trend 1 day ago
87%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CRDL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TCBPY0.300.04
+13.21%
TC BioPharm (Holdings) plc
ACMT33.00N/A
N/A
ACMAT Corp.
KAJMY22.28N/A
N/A
Kajima Corp.
CLCMF2.87N/A
N/A
Sinch AB
CMVLF3.12N/A
N/A
Cellectis Romainville

CRDL and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRDL has been loosely correlated with ACB. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if CRDL jumps, then ACB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDL
1D Price
Change %
CRDL100%
+4.47%
ACB - CRDL
33%
Loosely correlated
+16.29%
TLRY - CRDL
32%
Poorly correlated
+41.82%
EOLS - CRDL
32%
Poorly correlated
-2.20%
LNTH - CRDL
31%
Poorly correlated
-1.98%
SCYX - CRDL
30%
Poorly correlated
+4.14%
More

EOLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EOLS has been loosely correlated with PRGO. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if EOLS jumps, then PRGO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EOLS
1D Price
Change %
EOLS100%
-2.20%
PRGO - EOLS
41%
Loosely correlated
-2.35%
LNTH - EOLS
34%
Loosely correlated
-1.98%
AMRX - EOLS
32%
Poorly correlated
+3.51%
AKBA - EOLS
28%
Poorly correlated
-2.05%
ALKS - EOLS
28%
Poorly correlated
-0.64%
More